Filing Details
- Accession Number:
- 0001831942-25-000007
- Form Type:
- 13G Filing
- Publication Date:
- 2025-07-01 20:00:00
- Filed By:
- Commodore Capital
- Company:
- Cidara Therapeutics Inc. (NASDAQ:CDTX)
- Filing Date:
- 2025-07-02
- SEC Url:
- 13G Filing
Ownership Summary
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
Name | Beneficially Owned Number of Shares | Beneficially Owned Number of Aggregate Shares | Percent of Class |
---|---|---|---|
Commodore Capital LP | 0 | 1,175,000 | 5.5% |
Commodore Capital Master LP | 0 | 1,175,000 | 5.5% |
Robert Egen Atkinson | 0 | 1,175,000 | 5.5% |
Michael Kramarz | 0 | 1,175,000 | 5.5% |
Filing
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13G
|
UNDER THE SECURITIES EXCHANGE ACT OF 1934
|
Cidara Therapeutics, Inc. (Name of Issuer) |
Common Stock, par value $0.0001 per share (Title of Class of Securities) |
171757206 (CUSIP Number) |
06/25/2025 (Date of Event Which Requires Filing of this Statement) |
Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
![]() |
![]() |
![]() |
SCHEDULE 13G
|
CUSIP No. | 171757206 |
1 | Names of Reporting Persons
Commodore Capital LP | ||||||||
2 | Check the appropriate box if a member of a Group (see instructions)
![]() ![]() | ||||||||
3 | Sec Use Only | ||||||||
4 | Citizenship or Place of Organization
DELAWARE
| ||||||||
Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
1,175,000.00 | ||||||||
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
![]() | ||||||||
11 | Percent of class represented by amount in row (9)
5.5 % | ||||||||
12 | Type of Reporting Person (See Instructions)
IA, PN |
SCHEDULE 13G
|
CUSIP No. | 171757206 |
1 | Names of Reporting Persons
Commodore Capital Master LP | ||||||||
2 | Check the appropriate box if a member of a Group (see instructions)
![]() ![]() | ||||||||
3 | Sec Use Only | ||||||||
4 | Citizenship or Place of Organization
CAYMAN ISLANDS
| ||||||||
Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
1,175,000.00 | ||||||||
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
![]() | ||||||||
11 | Percent of class represented by amount in row (9)
5.5 % | ||||||||
12 | Type of Reporting Person (See Instructions)
PN |
SCHEDULE 13G
|
CUSIP No. | 171757206 |
1 | Names of Reporting Persons
Robert Egen Atkinson | ||||||||
2 | Check the appropriate box if a member of a Group (see instructions)
![]() ![]() | ||||||||
3 | Sec Use Only | ||||||||
4 | Citizenship or Place of Organization
UNITED STATES
| ||||||||
Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
1,175,000.00 | ||||||||
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
![]() | ||||||||
11 | Percent of class represented by amount in row (9)
5.5 % | ||||||||
12 | Type of Reporting Person (See Instructions)
HC, IN |
SCHEDULE 13G
|
CUSIP No. | 171757206 |
1 | Names of Reporting Persons
Michael Kramarz | ||||||||
2 | Check the appropriate box if a member of a Group (see instructions)
![]() ![]() | ||||||||
3 | Sec Use Only | ||||||||
4 | Citizenship or Place of Organization
UNITED STATES
| ||||||||
Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
1,175,000.00 | ||||||||
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
![]() | ||||||||
11 | Percent of class represented by amount in row (9)
5.5 % | ||||||||
12 | Type of Reporting Person (See Instructions)
HC, IN |
SCHEDULE 13G
|
Item 1. | ||
(a) | Name of issuer:
Cidara Therapeutics, Inc. | |
(b) | Address of issuer's principal executive offices:
6310 Nancy Ridge Drive, Suite 101, San Diego, CALIFORNIA, 92121. | |
Item 2. | ||
(a) | Name of person filing:
Commodore Capital LP
Commodore Capital Master LP
Robert Egen Atkinson
Michael Kramarz
Each a "Filer." | |
(b) | Address or principal business office or, if none, residence:
The address for Commodore Capital LP, Robert Egen Atkinson, and Michael Kramarz is 444 Madison Avenue, Floor 35, New York, NY 10022.
The address for Commodore Capital Master LP is Ugland House, South Church Street, PO Box 309, Grand Cayman KY1-1104, Cayman Islands. | |
(c) | Citizenship:
See Item 4 of the cover page for each Filer. | |
(d) | Title of class of securities:
Common Stock, par value $0.0001 per share | |
(e) | CUSIP No.:
171757206 | |
Item 3. | If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: | |
(a) | ![]() | |
(b) | ![]() | |
(c) | ![]() | |
(d) | ![]() | |
(e) | ![]() | |
(f) | ![]() | |
(g) | ![]() | |
(h) | ![]() | |
(i) | ![]() | |
(j) | ![]() please specify the type of institution: | |
(k) | ![]() | |
Item 4. | Ownership | |
(a) | Amount beneficially owned:
See Item 9 of the cover page for each Filer.
This report on Schedule 13G is being filed by Commodore Capital LP, a Delaware limited partnership (the "Firm"), Commodore Capital Master LP, a Cayman Islands exempted limited partnership ("Commodore Master"), Michael Kramarz, and Robert Egen Atkinson. The Firm is the investment manager to Commodore Master. As of June 25, 2025, the Firm may be deemed to beneficially own an aggregate of 1,175,000 shares of common stock, par value $0.0001 per share (the "Common Stock"), of Cidara Therapeutics, Inc. (the "Issuer"). The Firm, as the investment manager to Commodore Master, may be deemed to beneficially own these securities. Michael Kramarz and Robert Egen Atkinson are the managing partners of the Firm and exercise investment discretion with respect to these securities. Ownership percentages are based on 21,356,877 shares of Common Stock reported as issued and outstanding in the Issuer's Rule 424(b)(5) Prospectus Supplement filed with the Securities and Exchange Commission on June 24, 2025. | |
(b) | Percent of class:
See Item 11 of the cover page for each Filer. | |
(c) | Number of shares as to which the person has:
| |
(i) Sole power to vote or to direct the vote:
See Item 5 of the cover page for each Filer. | ||
(ii) Shared power to vote or to direct the vote:
See Item 6 of the cover page for each Filer. | ||
(iii) Sole power to dispose or to direct the disposition of:
See Item 7 of the cover page for each Filer. | ||
(iv) Shared power to dispose or to direct the disposition of:
See Item 8 of the cover page for each Filer. | ||
Item 5. | Ownership of 5 Percent or Less of a Class. | |
Item 6. | Ownership of more than 5 Percent on Behalf of Another Person. | |
Not Applicable
| ||
Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. | |
Not Applicable
| ||
Item 8. | Identification and Classification of Members of the Group. | |
Not Applicable
| ||
Item 9. | Notice of Dissolution of Group. | |
Not Applicable
|
Item 10. | Certifications: |
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
|
SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
|
|
|
|
|
|
Exhibit Information
|
Exhibit 1: Joint Filing Agreement |